Jazz Pharmaceuticals appoints vice president of r&d

Jeffrey Tobias also takes chief medical officer role

Jazz Pharmaceuticals, a US developer of pharmaceuticals for neurology and psychiatry based in Palo Alto, California, has appointed Jeffrey Tobias, as senior vice president of research and development and chief medical officer. He takes up his new roles on 17 October.

Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.

He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.

Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.

Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.

Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.

You may also like

Pharmaceutical

Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer

The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
Design & Build

Jazz Pharmaceuticals among ISPE FOYA winners

Ardmac supplied and installed the cleanroom in the biopharmaceutical company's winning facility in Ireland
Finance

Jazz concludes merger with Azur Pharma

Forms a specialist in CNS and women’s health products
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical

CellCarta and Leica Biosystems expand companion disgnostic development model partnership

Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Subscribe now